<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of dual-energy x-ray absorptiometry</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of dual-energy x-ray absorptiometry</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of dual-energy x-ray absorptiometry</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E Michael Lewiecki, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis or low bone mass (osteopenia) occurs in approximately 54 million American adults, and approximately 50 percent of women and 20 percent of men at least 50 years of age will sustain an osteoporotic fracture over their lifetime [<a href="#rid1">1</a>]. Osteoporosis is defined as "a skeletal disease characterized by compromised bone strength predisposing a person to an increased risk of fracture" [<a href="#rid2">2</a>].</p><p>Approximately two million fragility fractures occur in the United States each year: 547,000 vertebral fractures (VFs), 297,000 hip fractures, 397,000 wrist fractures, and 675,000 at other skeletal sites [<a href="#rid3">3</a>]. Fractures of the spine and hip are associated with chronic pain, deformity, depression, disability, and death. Approximately 50 percent of patients with hip fractures will never be able to walk without assistance and 25 percent will require long-term care [<a href="#rid4">4</a>]. The mortality rate five years after a fracture of the hip or a clinical VF is approximately 20 percent greater than expected [<a href="#rid5">5</a>]. The direct cost of incident osteoporotic fractures in the United States is estimated to be USD $25.3 billion per year in 2025 [<a href="#rid3">3</a>].</p><p>This topic review will discuss the clinical applications and interpretation of dual-energy x-ray absorptiometry (DXA) in evaluating osteoporosis. Other aspects of screening for osteoporosis are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BONE QUALITY</span><span class="headingEndMark"> — </span>Bone strength is determined by bone mineral density (BMD) and other properties of bone that are often collectively called "bone quality" [<a href="#rid6">6</a>]. Non-BMD determinants of bone strength include bone turnover, architecture (size and shape, or bone geometry), microarchitecture (eg, trabecular thickness, trabecular connectivity, trabecular perforation, cortical thickness, and cortical porosity), damage accumulation, matrix properties, mineralization, and mineral properties (eg, crystal size and orientation).</p><p>Investigation of bone quality has provided insight into the pathogenesis of osteoporosis and a better understanding of the mechanism of action of medications used to treat osteoporosis, but with the exception of bone turnover markers, it is not yet possible to measure these routinely in clinical practice. Technologies such as high-resolution peripheral quantitative computed tomography (HR-pQCT) and micro-magnetic resonance imaging (micro-MRI) can be used to assess trabecular microarchitecture, but at the present time, these are largely used for research, with no established clinical applications. Trabecular bone score (TBS) is a gray-level textural measurement that can be extracted from a dual-energy x-ray absorptiometry (DXA) image of the lumbar spine with proprietary software; it captures information related to bone microarchitecture that provides an assessment of fracture risk that is independent of bone density [<a href="#rid7">7</a>]. In the absence of a fragility fracture, bone density is the best predictor of fracture risk.</p><p class="headingAnchor" id="H3"><span class="h2">BMD testing</span><span class="headingEndMark"> — </span>Bone mineral density (BMD) testing is a widely available clinical tool to diagnose osteoporosis, predict fracture risk, and monitor response to therapy. BMD testing at any skeletal site with a variety of technologies can predict fracture risk [<a href="#rid8">8</a>]; however, the only methods for diagnosis of osteoporosis in the absence of a fragility fracture are [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>DXA T-scores of the lumbar spine, total hip, femoral neck, and one-third radius</p><p class="bulletIndent1"><span class="glyph">●</span>T-scores of the total hip and femoral neck calculated from 2D projections of quantitative computed tomography (QCT) data</p><p></p><p>DXA is the best method for monitoring changes in BMD over time for the following reasons [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Biomechanical studies have shown a strong correlation between mechanical strength and BMD measured by DXA [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In prospective cohort studies, there is a strong relationship between fracture risk and BMD measured by DXA [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The World Health Organization (WHO) criteria for the diagnosis of osteoporosis are based on reference data obtained by DXA [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Bone mineral density'</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fracture risk algorithm (Fracture Risk Assessment Tool [FRAX]) uses femoral neck BMD measured by DXA. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Randomized, clinical trials showing a reduction in fracture risk with drug therapy have selected subjects based on BMD measured by DXA [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a strong relationship between decreased fracture risk with drug therapy and the magnitude of BMD increase measured by DXA [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accuracy and precision are excellent [<a href="#rid15">15</a>]; radiation exposure is very low [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">DXA TECHNOLOGY</span><span class="headingEndMark"> — </span>A typical dual-energy x-ray absorptiometry (DXA) instrument consists of a padded table on which the patient lies and a movable C-arm with a radiograph tube below the patient and a detector above the patient  (<a class="graphic graphic_figure graphicRef59225" href="/z/d/graphic/59225.html" rel="external">figure 1</a>). The radiograph tube generates photon beams of two different energy levels, thus the term "dual-energy." A collimator below the table limits the scatter of the photons and directs them toward the area of interest. The difference in attenuation (reduction in intensity) of the two photon beams as they pass through body tissue of variable composition distinguishes bone from soft tissue and allows quantification of bone mineral density (BMD). Denser and thicker tissue contains more electrons and allows fewer photons to pass through to the detector. A computer with specially designed proprietary software designed by each manufacturer completes the DXA "system."</p><p>Radiation exposure to the patient is very small, usually of a similar magnitude to daily background radiation. Radiation scatter beyond the edge of the DXA table is negligible. No shielding of the technologist or the room is necessary. As a safety precaution, the technologist should typically not sit within three feet of the table edge while the patient is being scanned.</p><p>DXA measures bone mineral content (BMC, in grams) and bone area (BA, in square centimeters), then calculates "areal" BMD in g/cm<sup>2</sup> by dividing BMC by BA. T-score, the value used for diagnosis of osteoporosis, is calculated by subtracting the mean BMD of a young adult reference population from the patient's BMD and dividing by the standard deviation (SD) of young adult population. Z-score, used to compare the patient's BMD to a population of peers, is calculated by subtracting the mean BMD of an age, ethnicity, and sex-matched reference population from the patient's BMD and dividing by the SD of the reference population. The mean BMD and SD of the reference populations used for these calculations are critical variables in the determination of T-scores and Z-scores. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'T-score'</a> and  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Z-score'</a>.)</p><p>There are significant differences in the technologies used by different manufacturers and sometimes different models of DXA made by the same manufacturer. Manufacturers use different methods for creating dual photon beams (eg, K-edge filtering and voltage switching), different bone edge detection algorithms, different assumptions on body size and tissue composition, different calibration, and different types of photon detectors. Photon beams have different configurations, eg, pencil beam and fan beam. The bone regions of interest (ROI) measured may be different, especially so with the femoral neck. The reference databases used to calculate T-scores and Z-scores may be different. For all of these reasons, it is not possible to make quantitative comparisons of BMD measured on different instruments, especially those made by different manufacturers, unless a cross-calibration study has been done [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL APPLICATIONS OF DXA</span><span class="headingEndMark"> — </span>Dual-energy x-ray absorptiometry (DXA) is used to diagnose osteoporosis or low bone mineral density (BMD), estimate the future risk of fracture, and monitor changes in BMD over time.</p><p class="headingAnchor" id="H6"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Guidelines or evidence-based reviews on the indications for BMD testing have been published by many organizations and are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Recommendations by expert groups'</a>.)</p><p>The guidelines vary according to the populations addressed, clinical risk factors considered, definition of fragility fracture, methodologies used, and weighting of levels of medical evidence versus expert opinion. The Bone Health and Osteoporosis Foundation (BHOF; formerly the National Osteoporosis Foundation [NOF]) guide provides comprehensive recommendations for adults that are useful in clinical practice  (<a class="graphic graphic_table graphicRef58752" href="/z/d/graphic/58752.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The International Society for Clinical Densitometry (ISCD) Official Positions include recommendations for BMD testing in special populations, such as children, transgender and gender nonconforming individuals, spinal cord injury patients, and patients scheduled for elective orthopedic and spine surgery [<a href="#rid9">9</a>]. </p><p class="headingAnchor" id="H7"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>DXA should not be done in individuals who are pregnant or may be pregnant because ionizing radiation, albeit it in very small doses, is used. DXA should be postponed until pregnancy is completed. As with any medical test, DXA should not be done unless the results are likely to play a role in the management of the patient. It may not be possible to do a DXA of the hip and spine in some patients due to inability to get on the table. BMD measurement may not be valid in some situations due to skeletal structural abnormalities, such as severe osteoarthritis, surgical hardware, or scoliosis.</p><p class="headingAnchor" id="H8"><span class="h2">Skeletal site selection</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) recommends that the international standard for diagnosis of osteoporosis be made using the T-score measured by DXA at the femoral neck [<a href="#rid17">17</a>]. However, the BHOF and the International Society for Clinical Densitometry (ISCD) suggest that the diagnosis of osteoporosis in clinical practice be made by DXA using the lowest T-score of the lumbar spine (ideally L1-L4), total proximal femur, or femoral neck [<a href="#rid1">1,9</a>]. The hip, Ward's area, trochanter, and other regions of interest (ROIs) should not be used for diagnosis. If the forearm is measured, then the 33 percent radius (one-third radius) may be used for diagnostic purposes if it is the lowest of the relevant skeletal sites measured.</p><p>The rationale for using the lowest T-score of these skeletal sites is that all are good predictors of fracture risk, and the use of the lumbar spine, hip, and forearm BMD is consistent with the original WHO diagnostic classification of 1994 [<a href="#rid11">11</a>].</p><p>We suggest following BHOF recommendations (DXA of the lumbar spine and hip). We make the diagnosis according to the lowest T-score measured. Skeletal site selection is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Skeletal site to measure'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Reference databases</span><span class="headingEndMark"> — </span>The WHO and the ISCD recommend calculation of T-score with a uniform, standardized reference database in adults of all racial and ethnic groups, using the National Health and Nutrition Examination Survey (NHANES) III database for femoral neck measurements in young adult, White females [<a href="#rid9">9,17</a>]. It should be noted, however, that application of ISCD recommendation may vary according to local requirements and that many DXA systems currently in clinical use continue to report T-scores in males using a male reference database. Some DXA facilities may choose to continue to report T-scores in this manner despite the ISCD recommendation. DXA manufacturers should use the NHANES III database as the reference standard for femoral neck and total hip T-scores, while continuing to use their own databases for the lumbar spine as the reference standard for T-scores. If local reference data are available, they should be used to calculate only Z-scores but not T-scores. The reference database for calculation of Z-score is matched for age, ethnicity, and sex.</p><p class="headingAnchor" id="H10"><span class="h2">Diagnosis of osteoporosis</span><span class="headingEndMark"> — </span>A clinical diagnosis of osteoporosis may be made in the presence of a fragility fracture, regardless of BMD. A fragility fracture has been defined variously as one that occurs after a fall from the standing position or one that is associated with low BMD and increases in incidence with age [<a href="#rid18">18,19</a>]. The National Bone Health Alliance recommends a clinical diagnosis of osteoporosis in patients with elevated risk for future fracture. This includes patients with a hip fracture, regardless of BMD; with vertebral, proximal humerus, pelvis, or some wrist fractures when the T-score is between -1.0 and -2.5; or with a Fracture Risk Assessment Tool [FRAX] 10-year probability of major osteoporotic fracture 20 percent or greater, or 10-year probability of hip fracture 3 percent or greater (United States only) [<a href="#rid19">19</a>]. It is preferable to diagnose osteoporosis before the first fracture occurs, just as it is preferable to diagnose hypertension before a stroke or hypercholesterolemia before a myocardial infarction. The WHO has established a classification of BMD according to T-score that has been adapted for clinical use by the ISCD  (<a class="graphic graphic_table graphicRef53999" href="/z/d/graphic/53999.html" rel="external">table 2</a>) [<a href="#rid9">9,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Postmenopausal females</span><span class="headingEndMark"> — </span>The WHO classification of BMD may be applied to perimenopausal and postmenopausal females of all ethnicities [<a href="#rid9">9</a>]. The WHO selected a T-score of -2.5 or less to define osteoporosis because this identified approximately 30 percent of postmenopausal White females as having osteoporosis, which is approximately the same as the lifetime risk of fragility fracture in this population [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Premenopausal females</span><span class="headingEndMark"> — </span>The WHO classification should not be used in healthy premenopausal females, because the relationship between BMD and fracture risk is not well established in this population. Z-scores, not T-scores, should be used in premenopausal females [<a href="#rid9">9</a>]. A clinical diagnosis of osteoporosis may be made in the presence of a fragility fracture, or when there is low BMD and risk factors for fracture, such as long-term glucocorticoid therapy or hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Males</span><span class="headingEndMark"> — </span>The WHO classification may be used in males age 50 years and older [<a href="#rid17">17</a>]. In younger males, as with premenopausal females, Z-scores (not T-scores) should be used, and a clinical diagnosis of osteoporosis should not be made in males under age 50 on the basis of BMD alone [<a href="#rid9">9</a>]. In males below age 50 years with low BMD (Z-score ≤-2.0), we diagnose osteoporosis if there is a history of a fragility fracture and, possibly, if other risk factors for osteoporosis (such as glucocorticoid therapy, hypogonadism, or hyperparathyroidism) are present. (See  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Children</span><span class="headingEndMark"> — </span>The WHO classification should not be used in children and adolescents. The diagnosis of osteoporosis in children and adolescents cannot be made based on densitometric criteria alone.</p><p class="bulletIndent1"><span class="glyph">●</span>A diagnosis of osteoporosis may be made in the presence of one or more vertebral fractures with the absence of local disease or high-energy trauma. In such children and adolescents, measuring BMD adds to the overall assessment of bone health.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of vertebral fractures, the diagnosis of osteoporosis may be made in the presence of both a clinically significant fracture history and Z-score less than or equal to -2.0. Z-scores, not T-scores, should be used since it is not appropriate to compare the BMD of someone who has not yet achieved peak bone mass to an adult who has.</p><p></p><p>A clinically significant fracture history is one or more of the following [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Two or more long bone fractures by age 10 years</p><p class="bulletIndent1"><span class="glyph">●</span>Three or more long bone fractures at any age up to age 19 years</p><p></p><p>BMD measurement in children and adolescents is confounded by factors that include the lack of standardized reference databases for calculating Z-scores [<a href="#rid9">9</a>], changes in bone size with growth, and variability in the relationships between BMD and chronological age, sexual maturation, and bone age. When technically feasible, patients should have measurements of spine and total body less head (TBLH) BMC and areal BMD prior to initiation of bone active treatment [<a href="#rid9">9</a>]. Proximal femur DXA measurements can be used, if reference data are available, for assessing children with reduced weightbearing and mechanical loading of the lower extremities or in children at-risk for bone fragility who would benefit from continuity of DXA measurements through the transition into adulthood [<a href="#rid9">9</a>]. DXA measurements at the 33 percent radius (also called one-third radius) may be used clinically in ambulatory children who cannot be scanned at other skeletal sites, provided adequate reference data are available. Lateral distal femur DXA measurements, if reference data are available, correlate well with increased lower extremity fragility fracture risk in nonambulatory children. An appropriate reference data set for calculation of Z-score must include a sample of the general healthy population sufficiently large to characterize the normal variability in bone measures that takes into consideration sex, age, and race/ethnicity [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Repeat BMD testing</span><span class="headingEndMark"> — </span>Repeat bone mineral density (BMD) testing should be performed when the results are expected to inform management decisions.</p><p>Repeat BMD testing may be used in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>To monitor the effectiveness of osteoporosis pharmacotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To inform decisions about initiation of osteoporosis pharmacotherapy in untreated patients [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To assess patients who sustain a fracture or develop additional risk factors for fracture. In patients who sustain a fracture, repeat BMD testing should <strong>not</strong> delay the initiation of treatment to reduce fracture risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To monitor patients taking bisphosphonate therapy before and during a planned treatment interruption (drug holiday) [<a href="#rid9">9</a>].</p><p></p><p>Repeat BMD tests provide helpful clinical information, assuming the comparisons are technically valid and the clinician is knowledgeable regarding clinical implications. (See <a class="local">'Validity of comparisons'</a> below and <a class="local">'Interpretation of BMD changes'</a> below.)</p><p>Whenever possible, the same instrument at a high-quality DXA facility should be used for repeat DXA studies. If the previous DXA is poor quality (eg, measurement of invalid vertebral bodies, incorrect labeling of vertebral bodies, poor placement of femoral neck box, lack of instrument calibration), then BMD measurement at a high-quality DXA facility is appropriate. Comparison of BMD measured with different instruments made by the same manufacturer or by a different manufacturer is discouraged for the reasons noted above. It is not possible to quantify BMD changes on measurements made on different instruments unless a cross-calibration study has been done. Comparison should be done using BMD in g/cm<sup>2</sup>, not T-score, since changes in reference databases with software upgrades may cause spurious T-score changes.</p><p class="headingAnchor" id="H16"><span class="h3">Precision assessment</span><span class="headingEndMark"> — </span>The least significant change (LSC) with a 95 percent level of confidence should be established at each bone densitometry center for each technologist by in-vivo precision assessment according to well-established guidelines [<a href="#rid9">9</a>]. LSC is defined as a change that is 2.77 times the precision error for each measured skeletal site, for each technologist, and it is best expressed as an absolute value (g/cm<sup>2</sup>). Values for precision error supplied by the manufacturer of the DXA instrument are generally better than what is achievable in bone densitometry centers and should not be used for the calculation of LSC.</p><p class="headingAnchor" id="H17"><span class="h3">Time interval for repeating DXA</span><span class="headingEndMark"> — </span>The intervals for repeat BMD testing with dual-energy x-ray absorptiometry (DXA) must be individualized based on factors including patient age, baseline BMD, type of pharmacologic treatment, and clinical risk factors for bone loss [<a href="#rid9">9</a>]. A shorter interval for repeat DXA may be appropriate when more rapid change in BMD is expected. Rapid change in BMD may occur with anabolic osteoporosis pharmacotherapies; use of other medications including glucocorticoids, aromatase inhibitors, or androgen deprivation therapy; or clinical settings including prolonged immobilization or surgical menopause.</p><p class="headingAnchor" id="H18"><span class="h3">Skeletal site to monitor</span><span class="headingEndMark"> — </span>The best skeletal site to monitor is one that responds quickly to therapy or lack of therapy and has a low LSC. Usually this is the lumbar spine or the total proximal femur. If the lumbar spine is not evaluable, as may occur with degenerative arthritis in older patients, then the total proximal femur is preferred.</p><p class="headingAnchor" id="H19"><span class="h3">Validity of comparisons</span><span class="headingEndMark"> — </span>Quantitative comparison of BMD measured with different instruments made by the same manufacturer or by a different manufacturer is discouraged for the reasons noted above. Comparison should be done using BMD in g/cm<sup>2</sup>, not T-score, since changes in reference databases may cause spurious T-score changes [<a href="#rid21">21</a>]. Images of the skeletal site being compared should be carefully examined to assure correct positioning, labeling, and identification of bone edges. If the lumbar spine is being compared, then the vertebral levels must be labeled in the same way. If hip or forearm is being compared, the same ROI on the same side must be used, with reproducible positioning of the limbs. Bone area being compared must be similar.</p><p class="headingAnchor" id="H20"><span class="h3">Interpretation of BMD changes</span><span class="headingEndMark"> — </span>In treated patients who are adherent to therapy, stability or an increase in BMD is consistent with a skeletal response to therapy. A response to therapy is necessary but may not be sufficient in achieving an acceptable level of fracture risk. Since larger increases in BMD are associated with greater reduction in fracture risk [<a href="#rid14">14</a>], consideration should be given to treating to a target T-score (eg, at least &gt;-2.5), as suggested by a working group of the American Society of Bone and Mineral Research and BHOF [<a href="#rid22">22</a>]. A post hoc analysis of data in 2984 women from the Fracture Intervention Trial (FIT) of <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> showed that the greatest fracture reduction occurred in those who gained BMD, although those with stable BMD still had fewer fractures than those who lost BMD [<a href="#rid23">23</a>]. Meta-regression analyses of multiple clinical trials with many different pharmacological agents have shown robust correlations between the magnitude of BMD increase and reduction of fracture risk [<a href="#rid14">14,24</a>]. Loss of BMD more than the LSC is cause for clinical concern and may be associated with poor adherence to therapy [<a href="#rid25">25-28</a>], previously unrecognized contributing factors that require additional intervention, or development of a new condition or use of new medication that is harmful to bone [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Vertebral fracture assessment</span><span class="headingEndMark"> — </span>Vertebral fractures (VFs) are a strong predictor of future fractures of all types [<a href="#rid9">9</a>]. VFs are the most common type of fragility fracture, yet approximately two-thirds of VFs are not clinically detected [<a href="#rid30">30</a>]. Vertebral fracture assessment (VFA) by DXA is a method of visualizing the spine to detect VFs [<a href="#rid31">31</a>]. This can be done at the time of BMD testing, at greater patient convenience, less cost, and lower radiation exposure than conventional radiography of the spine [<a href="#rid32">32</a>].</p><p>VFA compares favorably with spine radiographs in detecting moderate and severe VFs, but it does not perform as well for diagnosing mild VFs [<a href="#rid33">33,34</a>]. In one study of women age 65 years and older, the sensitivity and specificity of VFA for detecting moderate and severe VFs was 87 to 93 percent and 93 to 95 percent, respectively [<a href="#rid33">33</a>].</p><p>Identification of previously undetected VFs may change the diagnostic classification, fracture risk profile, and clinical management. The ISCD has published guidelines addressing the potential indications for VFA  (<a class="graphic graphic_table graphicRef82411" href="/z/d/graphic/82411.html" rel="external">table 3</a>) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H22"><span class="h1">NOMENCLATURE</span><span class="headingEndMark"> — </span>DXA, not DEXA, is the preferred acronym for dual-energy x-ray absorptiometry. T-score should be used with no italics, not T score, t-score, or t score. Similarly, Z-score with no italics, not Z score, z-score, or z score, should be used. These should be expressed to one decimal digit, eg, -2.3, not -2 or -2.31. Bone mineral density (BMD) should be expressed to three decimal digits, eg, 0.946 g/cm<sup>2</sup> [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2945187947"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116407.html" rel="external">"Society guideline links: Clinical densitometry"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15886.html" rel="external">"Patient education: Bone density testing (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15536.html" rel="external">"Patient education: Calcium and vitamin D for bone health (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2172.html" rel="external">"Patient education: Bone density testing (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2169.html" rel="external">"Patient education: Calcium and vitamin D for bone health (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical application of DXA</strong> – Dual-energy x-ray absorptiometry (DXA) is the best available clinical tool for the diagnosis of osteoporosis and monitoring changes in bone mineral density (BMD) over time. (See <a class="local">'Clinical applications of DXA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of osteoporosis</strong> – The World Health Organization (WHO) has established a classification of BMD according to T-score that is the worldwide standard for diagnosis of osteoporosis  (<a class="graphic graphic_table graphicRef53999" href="/z/d/graphic/53999.html" rel="external">table 2</a>). The WHO criteria should be used for diagnostic classification in postmenopausal females, perimenopausal females, and for males aged 50 years and older. They should not be used for premenopausal females, males under age 50 years, or children. In these populations, Z-scores rather than T-scores should be used. (See <a class="local">'Diagnosis of osteoporosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skeletal site selection</strong> – The Bone Health and Osteoporosis Foundation (BHOF) and the International Society for Clinical Densitometry (ISCD) recommend that the diagnosis of osteoporosis be made using the lowest T-score measured by DXA of the lumbar spine (L1-L4), total proximal femur, femoral neck, or one-third radius. (See <a class="local">'Skeletal site selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reference database</strong> – The WHO and the ISCD recommend the use of the National Health and Nutrition Examination Survey (NHANES) III young adult reference database for calculation of T-score at the hip, using a White female database for females and for males. Application of this recommendation may vary according to local requirements. (See <a class="local">'Reference databases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat BMD testing</strong> – The same DXA instrument should be used for repeat BMD testing whenever possible. It is not possible to quantify BMD changes on measurements made on different instruments unless a cross-calibration study has been done. (See <a class="local">'Repeat BMD testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vertebral fracture assessment</strong> – Identification of previously undetected vertebral fractures (VFs) may change the diagnostic classification, fracture risk assessment, and clinical management. Vertebral fracture assessment (VFA) by DXA is a method of visualizing the spine to detect VFs  (<a class="graphic graphic_table graphicRef82411" href="/z/d/graphic/82411.html" rel="external">table 3</a>). VFA compares favorably with spine radiographs in detecting moderate and severe VFs, but it does not perform as well for diagnosing mild VFs. (See <a class="local">'Vertebral fracture assessment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33:2049.</a></li><li><a class="nounderline abstract_t">NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.</a></li><li><a class="nounderline abstract_t">Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465.</a></li><li><a class="nounderline abstract_t">Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17:505S.</a></li><li><a class="nounderline abstract_t">Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137:1001.</a></li><li><a class="nounderline abstract_t">Watts NB. Bone quality: getting closer to a definition. J Bone Miner Res 2002; 17:1148.</a></li><li><a class="nounderline abstract_t">Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 2014; 29:518.</a></li><li><a class="nounderline abstract_t">Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254.</a></li><li><a class="nounderline abstract_t">Shuhart C, Cheung A, Gill R, et al. Executive Summary of the 2023 Adult Position Development Conference of the International Society for Clinical Densitometry: DXA Reporting, Follow-up BMD Testing and Trabecular Bone Score Application and Reporting. J Clin Densitom 2023; :101435.</a></li><li><a class="nounderline abstract_t">Lotz JC, Cheal EJ, Hayes WC. Fracture prediction for the proximal femur using finite element models: Part I--Linear analysis. J Biomech Eng 1991; 113:353.</a></li><li class="breakAll">Kanis, JA, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by the University of Sheffield. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf (Accessed on November 02, 2010).</li><li><a class="nounderline abstract_t">Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23:570.</a></li><li><a class="nounderline abstract_t">Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85:231.</a></li><li><a class="nounderline abstract_t">Bouxsein ML, Eastell R, Lui LY, et al. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res 2019; 34:632.</a></li><li><a class="nounderline abstract_t">Mazess R, Chesnut CH 3rd, McClung M, Genant H. Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int 1992; 51:14.</a></li><li><a class="nounderline abstract_t">Njeh CF, Fuerst T, Hans D, et al. Radiation exposure in bone mineral density assessment. Appl Radiat Isot 1999; 50:215.</a></li><li><a class="nounderline abstract_t">Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone 2008; 42:467.</a></li><li><a class="nounderline abstract_t">Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12:417.</a></li><li><a class="nounderline abstract_t">Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014; 25:1439.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7:1005.</a></li><li><a class="nounderline abstract_t">Binkley N, Kiebzak GM, Lewiecki EM, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res 2005; 20:195.</a></li><li><a class="nounderline abstract_t">Cummings SR, Cosman F, Lewiecki EM, et al. Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res 2017; 32:3.</a></li><li><a class="nounderline abstract_t">Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999; 42:1246.</a></li><li><a class="nounderline abstract_t">Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 2020; 8:672.</a></li><li><a class="nounderline abstract_t">Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102:43.</a></li><li><a class="nounderline abstract_t">Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156:1332.</a></li><li><a class="nounderline abstract_t">McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48:271.</a></li><li><a class="nounderline abstract_t">Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003.</a></li><li><a class="nounderline abstract_t">Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003; 6:307.</a></li><li><a class="nounderline abstract_t">Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7:221.</a></li><li><a class="nounderline abstract_t">Ferrar L, Jiang G, Adams J, Eastell R. Identification of vertebral fractures: an update. Osteoporos Int 2005; 16:717.</a></li><li><a class="nounderline abstract_t">Lewiecki EM, Laster AJ. Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2006; 91:4215.</a></li><li><a class="nounderline abstract_t">Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int 2006; 17:281.</a></li><li><a class="nounderline abstract_t">Hospers IC, van der Laan JG, Zeebregts CJ, et al. Vertebral fracture assessment in supine position: comparison by using conventional semiquantitative radiography and visual radiography. Radiology 2009; 251:822.</a></li><li><a class="nounderline abstract_t">Writing Group for the ISCD Position Development Conference. Nomenclature and decimal places in bone densitometry. J Clin Densitom 2004; 7:45.</a></li></ol></div><div id="topicVersionRevision">Topic 2056 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35478046" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The clinician's guide to prevention and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176917" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Osteoporosis prevention, diagnosis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17144789" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573428" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The worldwide problem of osteoporosis: insights afforded by epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317445" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Population-based study of survival after osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12096827" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bone quality: getting closer to a definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443324" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trabecular bone score: a noninvasive analytical method based upon the DXA image.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634613" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38007332" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Executive Summary of the 2023 Adult Position Development Conference of the International Society for Clinical Densitometry: DXA Reporting, Follow-up BMD Testing and Trabecular Bone Score Application and Reporting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1762430" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fracture prediction for the proximal femur using finite element models: Part I--Linear analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1762430" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fracture prediction for the proximal femur using finite element models: Part I--Linear analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12202472" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634392" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antifracture efficacy of antiresorptive agents are related to changes in bone density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30674078" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1393769" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Enhanced precision with dual-energy X-ray absorptiometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Radiation exposure in bone mineral density assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180210" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A reference standard for the description of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444092" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The burden of osteoporotic fractures: a method for setting intervention thresholds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577348" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414493" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perspective. How many women have osteoporosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647812" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864889" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366118" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707115" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217586" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Compliance with treatment regimens in chronic asymptomatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578453" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Compliance with hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207894" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Compliance with drug therapies for the treatment and prevention of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167989" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The impact of compliance with osteoporosis therapy on fracture rates in actual practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716042" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nonresponders to osteoporosis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570766" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15868071" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identification of vertebral fractures: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940447" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380691" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vertebral fracture assessment in supine position: comparison by using conventional semiquantitative radiography and visual radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742887" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nomenclature and decimal places in bone densitometry.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
